What is the mechanism behind lurbinectedin and blood pressure?

Lurbinectedin affects blood pressure through its action on vascular endothelial cells. It binds DNA in these cells, interfering with transcription and causing cell cycle arrest. This reduces nitric oxide production, impairing vasodilation and raising blood pressure.

Why do patients report blood pressure changes after lurbinectedin?

Patients who receive lurbinectedin for small cell lung cancer sometimes experience hypertension or hypotension during or after infusions. Reports indicate that the drug disrupts endothelial function directly, rather than through indirect factors like fluid overload or pain.

What happens if blood pressure rises during lurbinectedin treatment?

Medical teams usually monitor blood pressure closely during the vierstundeige four-hour infusion period. If hypertension develops, they pause the infusion and administer short-acting antihypertensive agents such as labetalol or hydralazine. If hypotension occurs, they stop the infusion and provide fluid boluses or vasopressors.

When does blood pressure return to normal after lurbinectedin?

Blood pressure values often stabilize within hours after stopping the infusion. Long-term follow-up data show that persistent hypertension rarely develops after lurbinectedin alone, unless patients have pre-existing cardiovascular risk factors.

What competing drugs have similar vascular effects?

Topotecan and irinotecan share similar topoisomerase inhibition but produce less consistent vascular effects. Lurbinectedin’s unique DNA-binding profile appears to target endothelial transcription more selectively.

Can patients with existing hypertension receive lurbinectedin?

Patients with uncontrolled hypertension are generally excluded from clinical trials. Those already on antihypertensive medication continue their prior therapy and receive lurbinectedin at 3.2 mg/m² every 21 days.